Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.


Founders Jinzi Wu


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 3
Average round size
The average size of a deal this fund participated in
Portfolio companies 1
Rounds per year 0.30
Lead investments 1
Follow on index
How often the fund supports its portfolio startups at next rounds
Key employees 1

Areas of investment

  • Biotechnology
  • Therapeutics
  • Biopharma

In 2011 was created Ascletis, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the Chapel Hill. The venture was found in North America in United States.

Among the most popular portfolio startups of the fund, we may highlight Sagimet Biosciences. Besides, a startup needs to be aged 11-15 years to get the investment from the fund. Among the most successful fund investment fields, there are Biotechnology, Biopharma. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The important activity for fund was in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 deals per year.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Ascletis, startups are often financed by New Enterprise Associates, Kleiner Perkins, Rock Springs Capital. The meaningful sponsors for the fund in investment in the same round are Qianhai Ark, New Enterprise Associates, Kleiner Perkins. In the next rounds fund is usually obtained by Qianhai Ark, New Enterprise Associates, Kleiner Perkins.

The fund was created by Jinzi Wu.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Africa Enterprise Challenge Fund (AECF) -
Atoc Holdings Lynnwood, United States, Washington
Bainian Kangcheng China, Ningbo, Zhejiang
China Elite Capital -
CNN Atlanta, Georgia, United States
H2 Investment Properties California, San Francisco, United States
Hangzhou Maikasha China, Hangzhou, Zhejiang
Intel Communications Fund California, Santa Clara, United States
JP Morgan New York, New York, United States
Kuntin Beijing, Beijing, China
OneLiberty Ventures Cambridge, Massachusetts, United States
OVO Indonesia, Jakarta, Jakarta Raya
Paragon Trust Connecticut, New Haven, United States
PYJ-Dynasty Venture Fund California, Santa Barbara, United States
Significant Capital Ventures Australia, Australian Capital Territory, Canberra
The Beacon Group Maine, Portland, United States
Vanderlande Netherlands, North Brabant, Veghel

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Sagimet Biosciences

$80M11 Feb 2021 California, United States

Sagimet Biosciences

$7M05 Aug 2019 California, United States

Sagimet Biosciences

$18M13 Feb 2019 California, United States
Sagimet Biosciences Raises $80M in Crossover Financing

– Sagimet Biosciences, a San Mateo, Calif.-based clinical-stage biotechnology company, raised $80m in crossover financing.
– The round was led by an undisclosed public equity healthcare investment fund with participation from existing investors (including Ascletis, Kleiner Perkins, New Enterprise Associates (NEA) and Rock Springs Capital) along with new investors (Altium Capital, HM Capital, Invus and PFM Health Sciences).
– The company intends to use the funds to advance its lead program, TVB-2640 for NASH, to explore additional indications, to file an IND on a second FASN inhibitor, TVB-3567, by the end of 2021.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Ascletis?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: